Nicole Winchell

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, Jakub Svoboda, Sunita D. Nasta et al. · Blood · 2018 · 85 citations

Life Sciences, Immunology, Oncology +14

Prediction of lymphoma response to CAR T cells by deep learning-based image analysis

Yubing Tong, Jayaram K. Udupa, Emeline Chong et al. · PLoS ONE · 2023 · 23 citations · Full text

Medicine, Hematology, Oncology +17

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Elise A. Chong, Jakub Svoboda, Sunita D. Nasta et al. · Blood · 2016 · 22 citations

Life Sciences, Hematology, Oncology +17

Tandem Induction Radiation and Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

W. Tristram Arscott, David S. Miller, Joshua Jones et al. · International Journal of Radiation Oncology*Biology*Physics · 2018 · 19 citations

Medicine, Oncology, Radiation Oncology +14

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas

Stephen J. Schuster, Jakub Svoboda, Sunita D. Nasta et al. · Blood · 2016 · 19 citations

Life Sciences, Hematology, Immunology +13